MIV Therapeutics Inc (fka MIVI)

[Renee]

MIVI revoked:

http://www.sec.gov/litigation/admin/2014/34-71356.pdf

[Lucky40]

It's going to go to grey market soon than shutdown.. Thank god a long time
I tried to buy a lot of shares and only ended up getting 17.. Which it was less than commission.

[croesusjr]

Thanks for the information.

[Renee]

MIVI SEC Suspension:

http://www.sec.gov/litigation/suspensions/2013/34-70782.pdf

Order:

http://www.sec.gov/litigation/suspensions/2013/34-70782-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2013/34-70783.pdf

[jimmyy]

New CEO of MIV issued a press release. Looks like this one still has some hope left in it.

MIV THERAPEUTICS INC WELCOMES ITS NEW LEADER

May 18th, 2013 MIV Therapeutics, Inc. (the 'Company' or 'MIV') announced
today that MIV accept the resignation of Mr. Chris Chen as director and
officer while welcome its new leader, Chairman & CEO Mr. XIAO.

Mr. XIAO says, ' Even though the company has experience lots of turmoil for
the last few years but I do have the confidence to move it forward. We are
currently working with a medical fund to be our strategic partner so as to
initiate the CE Marking application. It's time now to reveal the real value
of the technologies and bring back our shareholders investment returns.

Nevertheless, the company has been bothering by its former US based patent
lawyer Mr. John Rissman along with his collection agent Mr. Alan Cohen,
those who might possibly in the future proved to be wrongly using
unnecessary and inappropriate means including using fraudulent and
illegally obtained documents to treat their opponents, as their way of
business doing. Whether or not this is true, we will definitely find out.

I believe my special expertise would help me better deal with the enemies
in the market place who have been bringing turmoil to the company and
smooth whatever possible transaction. It's time for the company to prevail.
I will launch a full investigation to conduct a legitimate searching while
taking the company to positive cash flow era.

With the sufficient clinical data, we are in the position of a great
advantage and huge potential markets in Asia, Europe as well as South
America.'

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is a development stage company in the business of
developing next-generation coatings and drug-delivery systems for
cardiovascular stents and other implantable medical devices.

[grapeman]

I thought this company was gone and had closed shop.
Do you really think this adds value to anyone with MIVI stock, or willthey sell it for a dime and all value will be sitting in an Indian company?

[nightwish]

NEWS

http://www.blogspan.net/presse/eans-news-miv-therapeutics-inc-miv-therapeutics-update-on-contracts/mitteilung/296426/

Richmond BC (euro adhoc) – April 30, 2012, Vancouver, British Columbia (OTC
Pinks: MIVI) MIV Therapeutics, Inc. (the “Company” or “MIV”) announced that MIV
finalize the arrangement of payment with Purple Medical Solution of India for
the sale of MIV India division, in which accordingly to the fifth amended Sale
and Purchase Agreement between the two parties, Purple Medial Solution will
settle the outstanding balance by monthly payment before Oct 2012, with
immediate effect.
Furthermore,the two parties will continue to endeavor to a new structure in
order to inject an operating stent manufacturer with significant revenue and
profit as major shareholder of current MIV Therapeutics, and MIV will develop
further market expansion as well as CE marking accreditation for the best
interest of all shareholders.
MIV has also engaged one of the leading IR companies Euro Ad Hoc as its agent in
Europe to facilitate the investors relationship as part of MIV’s further
marketing and branding process as part of the strategic plan.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is a development stage company in the business of
developing next-generation coatings and drug-delivery systems for cardiovascular
stents and other implantable medical devices.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the information
presented in this news release constitutes “forward-looking statements” as such
term is used in applicable United States and Canadian laws. These statements
relate to analyses and other information that are based on forecasts of future
results, estimates of amounts not yet determinable and assumptions of
management. Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives, assumptions
or future events or performance (often, but not always, using words or phrases
such as “expects” or “does not expect”, “is expected”, “anticipates” or “does
not anticipate”, “plans, “estimates” or “intends”, or stating that certain
actions, events or results “may”, “could”, “would”, “might” or “will” be taken,
occur or be achieved) are not statements of historical fact and should be viewed
as “forward-looking statements”. Such forward looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements.

Forward looking statements are made based on management’s beliefs, estimates and
opinions on the date the statements are made and the Company undertakes no
obligation to update forward-looking statements if these beliefs, estimates and
opinions or other circumstances should change, except as required by applicable
law. Although the Company believes that the beliefs, plans, expectations and
intentions contained in this news release are reasonable, there can be no
assurance those beliefs, plans, expectations or intentions will prove to be
accurate. Such forward-looking statements reflect our current views with
respect to future events and are subject to certain risks, uncertainties and
assumptions, including, the risks and uncertainties outlined in our most recent
financial statements and reports filed with the United States Securities and
Exchange Commission (the “SEC”) (available at www.sec.gov) and with Canadian
securities administrators (available at www.sedar.com). Investors should
consider all of the information set forth herein and should also refer to the
risk factors disclosed in the Company’s periodic reports filed from time-to-time
with the SEC. The Company again cautions investors that the Company is not
up-to-date in its SEC or SEDAR filings. Pink OTC Markets has discontinued the
display of quotes on otcmarkets.com for the Company’s securities because the
Company’s securities have been labeled Caveat Emptor (Buyer Beware) and because
adequate current information has not been made available by the Company.

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy securities of the Company nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of
any such jurisdiction.

Contacts:
MIV Therapeutics, Inc.
Fax: [phone]

Further inquiry note:
Fax: [phone]

[Saleen7]

Fifty percent MIVI discount, with one year buyback. 100,000 shares MIVI for $6,ooo. Will repurchase same for $12,000 in one year,if you wish. Saleen7.

[gabe1151]

So where is the good news

[Skylimit1959]

Hoping anyone can shed light on:
- what happened to MIV, why did they disappear from the news and reports after 2008/2009?
- what happened to the active trials that seemed to be going well and then nothing?
- In short, are they still alive and real; or do I take my loss?

thanks so much for any insight.
-Paul

[nightwish]

NEWS * Good NEWS * ONLY THE START


Taken from another board:

"MIV India to be sold

debt facility shows they are preparing for a price above 3 million USD.

PMSPL show after tax profit! and a 288 million rupie volume (above 5 million usd)!!!

MIVs market cap is something above 2 million USD...

insert-text-here

that sounds very good für MIV ...

cash comming in should be at least above 3 million usd.

dosco"

insert-text-here

[nightwish]

Who can find the article? A new one?


http://www.google.de/search?as_q=&as_epq=MIV+Therapeutics+MIVT+has+a+brand+new+clinical+advisor&as_oq=&as_eq=&hl=de&biw=1003&bih=511&lr=&cr=&as_ft=i&as_filetype=&as_qdr=all&as_occt=any&as_dt=i&as_sitesearch=&as_rights=&safe=images&btnG=Google-Suche

[grapeman]

Nightwish - You know the average volume here?

[nightwish]

"whole series of good news to release soon"

These words are taken from an e-mail which Chris Chen has sent to a German shareholder. You can find it here:

http://www.wallstreet-online.de/diskussion/1142545-1771-1780/miv-therapeutics-die-bergtour-beginnt


The whole e-mail:

"Thomas,

We have a whole series of good news to release soon. I will give you an update in the next couple of weeks.

Regards,

Chris"

[nightwish]

Great news: Read this e-mail from Chris Chen (Chair)

A shareholder from Germany posted today the following e-mail from Chris Chen (Chair, MIV Therapeutics) on a German investment board:

"Dear Thomas,

Ms. Denise Jong in HK forwarded your email to me in which I think it might be a good time to update you of some recent development of MIV for you.

1. The company is now in the process of auditing the financial in order to bring the trading active after SEC approval;

2. The company has signed a significant off-take agreement with Beijing based Chinese medical distributor for the MIV products once it obtains the permits from the Chinese government.

3. The company is now better structuring the transaction with the HK based investors and China mainland investors.

I hope the above information can be of help for you to better understanding we are moving forward positively and actively. Further details will be disclosed through news release for shareholders and investors.

On behalf of the company, thanks again for the continuous support of MIV.

Regards,

Chris Chen
Chair, MIV Therapeutics Inc."

[nightwish]

MIV Therapeutics on its way to many dollars?


MIV THERAPEUTICS ACCEPTS RESIGNATION OF CEO

February 9, 2011, Vancouver, British Columbia (OTC Pinks: MIVI) MIV Therapeutics, Inc. (the “Company” or “MIV”) announced that effective on February 4, 2011, the Board of Directors of MIV accepted Patrick McGowan’s resignation as President, Chief
Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a Director and accepted the consent to act of Chris Chen to serve as President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of the Company.

As a consequence of the above resignation and appointment, Chris Chen is now the Company’s sole director and officer. The Company is now assembling a new board and management team with industry veterans to better facilitate the animal test and clinical
trials in China, as well as the certification of CE Marking in Europe.

The company has also immediately initiated the process of auditing to bring the financial statements up to date so that it can be in the position to accept the new investors from one of the largest medical group from Beijing, China.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is a development stage company in the business of developing next-generation coatings and drug-delivery systems for cardiovascular stents and other implantable medical devices.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the information presented in this news release
constitutes “forward-looking statements” as such term is used in applicable United States and Canadian
laws. These statements relate to analyses and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance (often, but not always, using words or phrases such as
“expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or
“intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking
statements”. Such forward looking statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forwardlooking
statements.
Forward looking statements are made based on management’s beliefs, estimates and opinions on the date
the statements are made and the Company undertakes no obligation to update forward-looking statements if
these beliefs, estimates and opinions or other circumstances should change, except as required by
applicable law. Although the Company believes that the beliefs, plans, expectations and intentions
contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or
intentions will prove to be accurate. Such forward-looking statements reflect our current views with
respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks
and uncertainties outlined in our most recent financial statements and reports filed with the United States
Securities and Exchange Commission (the “SEC”) (available at www.sec.gov) and with Canadian
securities administrators (available at www.sedar.com). Investors should consider all of the information set
4200319.1
forth herein and should also refer to the risk factors disclosed in the Company’s periodic reports filed from
time-to-time with the SEC. The Company again cautions investors that the Company is not up-to-date in its
SEC or SEDAR filings. Pink OTC Markets has discontinued the display of quotes on otcmarkets.com for
the Company’s securities because the Company’s securities have been labeled Caveat Emptor (Buyer
Beware) and because adequate current information has not been made available by the Company.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the
Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
Contacts:
MIV Therapeutics, Inc.
Fax: [phone]

[grapeman]

Article:
http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/01/13/prweb8061525.DTL&type=printable

[nightwish]

MIV Therapeutic´s VESTASYNC stent

http://www.faqs.org/patents/app/20110008232

"[0006]While extensively used in the hard tissue arena, the use of HAP as an alternative to polymers in drug delivery systems relevant to cardiovascular medical devices is currently under development for example MIV therapeutics VESTASYNC.TM. stent. Results recently reported on the clinical trial underway by MIV Therapeutics demonstrate no adverse clinical effects from the use of HAP-coated coronary stents.sup.(6)."

[grapeman]

Up 100% this week and noone noticed. Go Figure.

[nightwish]

Wow! We could have a winner here!

NEW DEAL AND NEW PARTY >>>>> May result in party, party, party ...

Wake UP AMERICA !!!


http://ih.advfn.com/p.php?pid=nmona&article=45892738

SECTION 8 - OTHER EVENTS


Item 8.01 Other Events.


On December 24, 2010, MIV Therapeutics, Inc. (the "Company") issued a news release announcing that it is that it is nearing the completion of an agreement regarding restructuring activities with a large medical investment group based in Asia to provide significant further funding to the Company.

The share purchase agreements that the Company entered into with CCT Tech International Limited ("CCT") and Innomed Scientific Limited ("Innomed"), which the Company announced in November, are being postponed so that the Company can better restructure the transaction, which senior management of the Company believes will result in a broader positive impact for the Company and its shareholders. The original agreements with CCT and Innomed were terminated according to Hong Kong securities commission listing rules because a new deal constitutes a material change. Senior management of the Company is in the final stage of completing definitive agreements with the new party.

In addition, the Company recently signed a Memorandum of Understanding with a Chinese distributor to provide the distributor with exclusive distribution rights for the Company's products for the major cities and provinces of China.

[grapeman]

Looks like on again.

[gabe1151]

However, CCT has extended time for MIVI to return deposit (April)...maybe deal can be resurrected

[gabe1151]

Looks like MIV sale to CCT not approved by CCT shareholders...cancelled!

[nightwish]

Approval for MIV Therapeutics India


insert-text-here

See under "6. Medical Devices"

[Arnold25764]

Yes, will follow more closely. Thanks!

[grapeman]

error or not following? up another 17% today. offices bought for med research.

[Arnold25764]

[grapeman]

Still following? Over next 20 days should see development.

[grapeman]

Worth paying attention again.

[grapeman]

The present is not so bad. Gone from .04to .43 this month,,, so not bad. Once totally financing is arranged and ini place company will do press release,, and then we will really see.



<<What will the future hold>>

[xiws]

What will the future hold
Well, there is volume, and pps increase, and news that isn't at all clear. Interesting times. We'll see where this goes when more is actually made known and deals are done. And how it actually affects any shareholders.

[grapeman]

more on buy out via yahoo board
Parties : (i) Purchaser : CCT Tech International Limited
(ii) Vendor : MIV Therapeutics, Inc.
(iii) Target Company : MIV Scientific Holdings Ltd.
unbeliveable what is going on here with MIV as vendor and the MIV subsidiary as target.

the target will be valued not less than 150 million!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
read this: http://www.cct-tech.com.hk/getfiles.php?...
under the firm site: http://www.cct-tech.com.hk/eng/investor/...
dosco

[grapeman]

Buyout hapening with Chinese. reoported.
http://translate.google.com/translate?hl=en&sl=zh-TW&u=http://www.etnet.com.hk/www/tc/stocks/realtime/quote_ca_sdi.php%3Fcode%3D261&prev=/search%3Fq%3DCCT%2BTelecom%2BMIV%2BTherapeutics%26start%3D30%26hl%3Den%26sa%3DN&rurl=translate.google.com&twu=1

[grapeman]

http://www.otcmarkets.com/stock/MIVI/company-info

[xiws]

Product good, company however...
Whatever might be the status of the vestasync product, it appears the MIVT itself is defunct. Website gone, no contacts, no executives, no SEC filings.
So, curiously, do you have other info on the company itself that is recent?

[nightwish]

MUST READ: ENTHUSIASTIC VERY LONG-TERM RESULTS OF VESTASYNC TRIAL



VERY LONG-TERM RESULTS (> 2 YEAR) OF THE VESTASYNC I TRIAL WITH A NOVEL, THIRD-GENERATION, HYDROXYAPATITE POLYMER-FREE SIROLIMUS-ELUTING STENT:

http://content.onlinejacc.org/cgi/reprint/55/10_MeetingAbstracts/A179.E1679.pdf

- "This information is current as of September 2, 2010"

- "Conclusion: The novel VES was effective in reducing LL and NIH at 4 and 9 months, with no evidence of late catch-up. Two-year clinical follow-up data showed maintenance of the enthusiastic initial findings.

- "Third year clinical follow-up data will be available at the meeting." (i2 Oral Contributions, Georgia World Congress Center, Room B315, Sunday, March 14, 2010, 4:30 p.m.-4:42 p.m.)


So the third year clinical follow-up data has to be great too if they have chosen to present the data at a congress meeting ...


VERY GOOD TIMES AHEAD FOR MIV THERAPEUTICS IMHO !!!

[nightwish]

Launch of VESTAsync stent mid/end 2010? So news soon?

I have found a German Report about MIV Therapeutics from 2008 which is very, very informative and interesting.

http://www.financial.de/imgs/newsletter/fde/080828/ResearchMIVdeutsch.pdf

Maybe you can translate the report into English by a translation machine.

The report mentions on page 14 that the launch of the VESTAsync stent is planned for mid/end of 2010 in the EU (FDA approval 2011).

So next months could be very interesting.

I have translated some highlights of the report:

VESTAsync ™ (Stent of the 3-rd generation)

- MIV's main product unites all advantages of the 2-nd generation DESs currently located in the market with the security profile of pure metal stents

- 60% less active substance in comparison to Johnson & Johnson's "Cypher" as Benchmark

- substantial shortening of the coagulation-restraining therapy with significant clinical implications

- quicker healing in comparison to Cypher ®

- in comparison to competition MIV has a projection of approx. 2.5 years

- Our assessment beginning proves a fair value of 12,70 $/share (with full dilution)

- Under consideration of the current market cap the stock is undervalued significantly.

[nightwish]

Any comments about the new CEO Patrick A. McGowan?

[Makamai]

Appreciate the reply - I could never figure out why it was taking this company so long to get their product tested and introduced to the market, unless it wasn't as good as was being publicized. Anyway, after the reverse split things have basically fallen apart so I've taken the tax loss finally and doing well on other plays.

GLTU Makamai

[xiws]

Last I heard - back in March
Had a conversation with investor relations. I've seen absolutely nothing since. Haven't called, either. Out of curiosity I just tried and the IR folks phone number from the website now responds as "not in service." No SEC filings since last year, other than the notice of inability to timely file. At that time good progress was made on the trials, from a medical standpoint, but had burned through so much cash they needed funds and were in conversations with possible partners, sources, etc. Market might have weakened around them by some other study announcements that stents in general may be less desirable than they had been previously thought.

[Makamai]

Silence by this company for so long is certainly not golden... I've held this stock for about 5 years but finally gave up a few weeks back and took my losses...

Makamai

[investplus]

Anybody here anymore. Anyone hear how the trials are going or if the company is going to make anything public?

[Arnold25764]

I still think there is potential in this company so i'll keep an eye out for updates. Thanks.

[Makamai]

They need to start generating some serious income to get back on folks radar. Looks like that's a year off or so...

Makamai

[Arnold25764]

Man this board is clearly dead. So much for MIVI!!

[Arnold25764]

Haven't heard much from these guys. Anyone have a clue whats going on? I sold my shares until i find out otherwise.

[Arnold25764]

Purchased stock in this company. What do you guys think about them? I think the technology looks very promising and noone is close to getting where they are at the moment. Only there hasn't been much news for a couple of weeks. I did contact them through email. They want to commercialize their product in mid 2010.

[TradeForProfits]

i think they will survive, yes. I agree their tech looks very promising.

[wshaw14]

MIV continues to enroll patients in the VESTASYNC II trial. It is anticipated that the VESTASYNC II results will form the basis of a regulatory filing for marketing approval in Europe in mid 2010. I like the tech and think it has great potential, but can mivi survive to benefit from it??

[TradeForProfits]

yup. definitely on the right track here imo.